Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 6;19(19):5414-5417.
doi: 10.1021/acs.orglett.7b02684. Epub 2017 Sep 14.

Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands

Alexander M Sherwood  1 , Samuel E Williamson  1 , Rachel S Crowley  1 , Logan M Abbott  1 , Victor W Day  1 , Thomas E Prisinzano  1
Affiliations

Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands

Alexander M Sherwood et al. Org Lett. .

Abstract

Informed by previous semisynthetic work on salvinorin A, a modular total synthesis has been developed capable of producing novel compounds targeting the κ-opioid receptor. The strategy has permitted the deliberate simplification and introduction of functionality about the target molecule to provide access to molecular features on salvinorin A otherwise unattainable by semisynthesis. Using this approach, a potent pseudo-neoclerodane κ-opioid receptor ligand (2) has been realized.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Salvinorin A (1) and representative semi-synthetic derivatives (3–7) in support of 3-point bind-ing model hypothesis. Values indicate fold-change in activity relative to 1 in the assay readout evaluated.
Figure 2
Figure 2
Disconnect strategy and retrosynthesis to 14-membered bisenone macrolide 8 that is capable of undergoing a diastereoselective transannular cascade reaction to 2.
Scheme 1
Scheme 1
Synthetic route to pseudo-neoclerodane 2 with unambiguous characterization by single crystal X-ray diffraction.
See this image and copyright information in PMC

References

    1. Ortega A, Blount JF, Manchand PS. J Chem Soc Perk Trans 1. 1982:2505.
    2. Valdes LJ, Butler WM, Hatfield GM, Paul AG, Koreeda M. J Org Chem. 1984;49:4716.
    3. Siebert DJ. J Ethnopharmacol. 1994;43:53. - PubMed
    4. Cunningham CW, Rothman RB, Prisinzano TE. Pharmacol Rev. 2011;63:316. - PMC - PubMed
    1. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB. Proc Natl Acad Sci U S A. 2002;99:11934. - PMC - PubMed
    2. Johnson MW, MacLean KA, Caspers MJ, Prisinzano TE, Griffiths RR. J Psychopharmacol. 2016;30:323. - PMC - PubMed
    1. Crowley RS, Riley AP, Sherwood AM, Groer CE, Shivaperumal N, Biscaia M, Paton K, Schneider S, Provasi D, Kivell BM, Filizola M, Prisinzano TE. J Med Chem. 2016;59:11027. - PMC - PubMed
    2. Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE. J Med Chem. 2005;48:4765. - PubMed
    1. Stein C. Annu Rev Med. 2016;67:433. - PubMed
    2. Warner M, Trinidad JP, Bastian BA, Minino AM, Hedegaard H. Natl Vital Stat Rep. 2016;65:1. - PubMed
    1. Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H. Xenobiotica. 2009;39:391. - PubMed

Publication types